alexa Abstract | Biopharmaceutics classification system- basis for waiver of in-vivobioavailability and bioequivalence studies

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access

Abstract

The Biopharmaceutical classification system (BCS) w as introduced by Amidon et al in 1995 to reduce the need for in vivo bioequivalence (BE) studies, utilization of in vitro dissolution tests as a surrogate for in v ivo bioequivalence studies. This step certainly reduces timelines in t he drug development process, both directly and indi rectly, and reduces unnecessary drug exposure in healthy volunt eers, which is the normal study population in BE st udies. The principles of the BCS classification system can be applied to NDA (New Drug Application) and ANDA (Abb reviated New Drug Application) approvals as well as to scale -up and post approval changes in drug manufacturing .

To read the full article Peer-reviewed Article PDF image

Author(s): Trivikram Rawat and I P Pandey

Keywords

Biopharmaceutics Classification System, solubility, permeability, dissolution, bioequivalence,immediate-release products., Biopharmaceutics, n-vivobioavailability, bioequivalence

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords